Noxa determines localization and stability of MCL-1 and consequently ABT-737 sensitivity in small cell lung cancer

Bibliographic Information

Published
2014-02-13
Resource Type
journal article
Rights Information
  • http://www.springer.com/tdm
DOI
  • 10.1038/cddis.2014.6
Publisher
Springer Science and Business Media LLC

Description

The sensitivity to ABT-737, a prototype BH3 mimetic drug, varies in a broad range in small cell lung cancer (SCLC) cells. We have previously shown that the expression of Noxa, a BH3-only pro-apoptotic BCL-2 family protein, is the critical determinant of ABT-737 sensitivity. We show here that Noxa regulates the localization and stability of MCL-1, an anti-apoptotic member, which results in modulating ABT-737 sensitivity. Mutations in Noxa within the BH3 domain, the carboxyl terminus mitochondrial targeting domain, or of ubiquitinated lysines not only change the localization and stability of Noxa itself but also affect the mitochondrial localization and phosphorylation/ubiquitination status of MCL-1 and consequently modulate sensitivity to ABT-737. Results of studies utilizing these mutant proteins indicate that Noxa recruits MCL-1 from the cytosol to the mitochondria. Translocation of MCL-1 initiates its phosphorylation and subsequent ubiquitination, which triggers proteasome-mediated degradation. The precise regulatory mechanisms of Noxa/MCL-1 expression and stability could provide alternative targets to modulate apoptosis induced by BH3 mimetic drugs or other chemotherapeutic reagents.

Journal

  • Cell Death & Disease

    Cell Death & Disease 5 (2), e1052-e1052, 2014-02-13

    Springer Science and Business Media LLC

Citations (3)*help

See more

References(28)*help

See more

Related Projects

See more

Details 詳細情報について

Report a problem

Back to top